4,782 Shares in Elevance Health, Inc. (NYSE:ELV) Bought by Nomura Holdings Inc.

Nomura Holdings Inc. purchased a new stake in Elevance Health, Inc. (NYSE:ELV) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 4,782 shares of the company’s stock, valued at approximately $2,255,000.

Other institutional investors also recently modified their holdings of the company. Sanders Capital LLC boosted its holdings in Elevance Health by 4.6% during the fourth quarter. Sanders Capital LLC now owns 4,457,986 shares of the company’s stock worth $2,102,208,000 after purchasing an additional 196,010 shares during the last quarter. Capital International Investors lifted its position in Elevance Health by 7.9% during the 4th quarter. Capital International Investors now owns 3,374,709 shares of the company’s stock worth $1,591,237,000 after buying an additional 248,150 shares in the last quarter. Baillie Gifford & Co. boosted its stake in shares of Elevance Health by 0.9% during the 4th quarter. Baillie Gifford & Co. now owns 3,087,904 shares of the company’s stock worth $1,456,132,000 after buying an additional 27,986 shares during the last quarter. Norges Bank bought a new position in shares of Elevance Health in the 4th quarter valued at about $1,347,434,000. Finally, Morgan Stanley increased its position in shares of Elevance Health by 1.7% in the third quarter. Morgan Stanley now owns 2,784,714 shares of the company’s stock valued at $1,212,521,000 after acquiring an additional 46,322 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ELV has been the subject of several recent research reports. Stephens reissued an “overweight” rating and set a $615.00 price target on shares of Elevance Health in a research report on Tuesday, June 11th. Truist Financial reissued a “buy” rating and issued a $600.00 price objective (up previously from $580.00) on shares of Elevance Health in a report on Friday, April 19th. Robert W. Baird started coverage on shares of Elevance Health in a report on Thursday, May 30th. They set an “outperform” rating and a $649.00 target price on the stock. UBS Group increased their price target on shares of Elevance Health from $585.00 to $605.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Finally, Royal Bank of Canada boosted their price objective on shares of Elevance Health from $574.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, April 19th. One research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Elevance Health currently has a consensus rating of “Buy” and an average price target of $607.36.

Elevance Health Stock Down 1.3 %

Elevance Health stock opened at $527.49 on Wednesday. The company’s 50-day moving average price is $530.25 and its two-hundred day moving average price is $505.90. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.54. The stock has a market cap of $122.60 billion, a P/E ratio of 19.94, a P/E/G ratio of 1.18 and a beta of 0.83. Elevance Health, Inc. has a twelve month low of $412.00 and a twelve month high of $550.34.

Elevance Health (NYSE:ELV) last announced its earnings results on Thursday, April 18th. The company reported $10.64 earnings per share for the quarter, topping analysts’ consensus estimates of $10.54 by $0.10. The company had revenue of $42.27 billion for the quarter, compared to analyst estimates of $42.49 billion. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the company earned $9.46 earnings per share. As a group, analysts expect that Elevance Health, Inc. will post 37.2 EPS for the current year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 25th. Stockholders of record on Monday, June 10th will be issued a dividend of $1.63 per share. The ex-dividend date is Monday, June 10th. This represents a $6.52 annualized dividend and a dividend yield of 1.24%. Elevance Health’s dividend payout ratio is presently 24.64%.

Insiders Place Their Bets

In other news, EVP Felicia F. Norwood sold 14,111 shares of Elevance Health stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $533.74, for a total value of $7,531,605.14. Following the transaction, the executive vice president now owns 31,460 shares in the company, valued at approximately $16,791,460.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.29% of the company’s stock.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.